-
Terumo Corporation has reported past full-year results for the 12 months to March 31, 2026, with sales rising to ¥1,131.88 billion and net income reaching ¥135.91 billion, alongside higher basic and diluted earnings per share from continuing operations compared with the prior year.
-
The combination of stronger revenue and earnings indicates that Terumo improved its profitability over the period, suggesting that recent operational initiatives and cost controls have been effective.
-
We'll now examine how Terumo's stronger full-year earnings and improved profitability reshape the company's investment narrative and future expectations.
Capitalize on the AI infrastructure supercycle with our selection of the 46 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
Terumo Investment Narrative Recap
To be a Terumo shareholder, you need to believe in steady global demand for medical devices and the company's ability to protect margins despite pricing and tariff pressures. The latest full year results, with higher sales and net income, support this profitability story in the near term, but they do not remove the key risk that tariffs and hospital procurement pressure could still squeeze margins if price increases become harder to push through.
The recent inauguration of the Terumo–Tata Elxsi Offshore Development Center is especially relevant here, as it aims to support product development, localization, and cost efficiency. In the context of stronger earnings, this development center could be an important operational lever if pricing pressure intensifies, although its financial impact will take time to show up and may not fully offset broader risks around tariffs and procurement dynamics.
However, investors should not overlook the possibility that persistent tariff and procurement pressure could still weigh on margins and cash flow...
Read the full narrative on Terumo (it's free!)
Terumo's narrative projects ¥1335.0 billion revenue and ¥195.4 billion earnings by 2029. This requires 6.8% yearly revenue growth and a ¥67.5 billion earnings increase from ¥127.9 billion today.
Uncover how Terumo's forecasts yield a ¥2872 fair value , a 20% upside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts were already cautious, assuming revenue of about ¥1,323.7 billion and earnings of ¥188.7 billion by 2029, so compared with the consensus catalysts they focus more on sustained pricing pressure and procurement risk as reasons why today's strong earnings might not fully address their concerns.
Explore 2 other fair value estimates on Terumo - why the stock might be worth as much as 31% more than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
-
A great starting point for your Terumo research is our analysis highlighting 4 key rewards that could impact your investment decision.
-
Our free Terumo research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Terumo's overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
-
Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
-
Explore 28 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
-
Find 17 companies with promising cash flow potential yet trading below their fair value .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 4543.T .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
